GlassScriptPhysician profile
Christopher W Parker
NPI 1518251735
$7,189.04
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,080 · 2020: $1,313 · 2021: $1,430 · 2022: $1,608 · 2023: $18.94 · 2024: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $700 · Food and Beverage: $58.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $700.34 |
| Food and Beverage | $58.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,280.78 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,214.55 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.73 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $755.34 | 2019-2022 | |
| Abiomed | $740.34 | 2024 | Impella |
| Insmed, INC. | $482.73 | 2019-2022 | |
| Advanced Respiratory, INC | $274.88 | 2019-2021 | |
| Genzyme Corporation | $209.48 | 2019-2022 | |
| Philips North America LLC | $148.99 | 2019-2023 | |
| Circassia INC. | $133.39 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $128.97 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.94 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $97.44 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.41 | 2019 | |
| Mylan Specialty L.P. | $79.16 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $76.64 | 2022 | |
| Amgen INC. | $74.66 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $74.29 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $57.56 | 2019-2022 | |
| Genentech USA, INC. | $55.04 | 2019-2022 | |
| Vapotherm INC | $54.77 | 2021 | |
| Ani Pharmaceuticals, INC. | $45.48 | 2022 | |
| Alexion Pharmaceuticals, INC. | $40.61 | 2021-2022 | |
| Veran Medical Technologies, INC. | $40.22 | 2020-2021 | |
| Electromed, INC. | $30.88 | 2019-2022 | |
| Optinose US, INC. | $24.05 | 2019 | |
| Shire North American Group INC | $21.00 | 2019 | |
| Covidien LP | $20.33 | 2020 | |
| United Therapeutics Corporation | $19.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.48 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.45 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.74 | 2020 | |
| Nabriva Therapeutics, Plc | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.